ABVX:NASDAQ
Abivax SA
$118.24
arrow_upward
+1.97%(+2.29) 1D
Sep 11, 3:53:43 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$115.46
High
$119.02
Low
$114.68
Mkt. cap
8.66B
Avg. vol.
929.05K
Volume
707.26K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
Open
$115.46
High
$119.02
Low
$114.68
Mkt. cap
8.66B
Avg. vol.
929.05K
Volume
707.26K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.35M
No. of employees
80
News stories
From web sources and news partners
GuruFocus
·
6 hours ago
Earnings To Watch: Abivax SA (XPAR:ABVX) Reports Q2 2026 Result
Benzinga
·
1 day ago
This Amer Sports Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Investing.com
·
1 day ago
Goldman Sachs initiates Abivax stock coverage with buy rating
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees80
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com